Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai

doi:10.1007/s11684-022-0977-3

Frontiers of Medicine

2023, Vol. 17

Issue (3): 562-575 https://doi.org/10.1007/s11684-022-0977-3

本期目录

Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai

Ziyu Fu¹, Dongguo Liang¹, Wei Zhang^1,², Dongling Shi³, Yuhua Ma⁴, Dong Wei⁵, Junxiang Xi¹, Sizhe Yang¹, Xiaoguang Xu¹, Di Tian³, Zhaoqing Zhu³, Mingquan Guo³, Lu Jiang¹, Shuting Yu¹, Shuai Wang¹, Fangyin Jiang¹, Yun Ling³, Shengyue Wang¹, Saijuan Chen¹(

), Feng Liu¹(

), Yun Tan¹(

), Xiaohong Fan³(

)

¹. Shanghai Institute of Hematology, National Research Center for Translational Medicine, State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai 200025, China
². National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi’an 710032, China
³. Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China
⁴. Department of Nephrology, Traditional Chinese Medicine Hospital of KunShan, Suzhou 215300, China
⁵. Department of Infectious Diseases, Ruijin Hospital Affiliated to Shanghai Jiao Tong University (SJTU) School of Medicine, Shanghai 200025, China

全文: PDF(5819 KB) HTML

Abstract：

The Omicron family of SARS-CoV-2 variants are currently driving the COVID-19 pandemic. Here we analyzed the clinical laboratory test results of 9911 Omicron BA.2.2 sublineages-infected symptomatic patients without earlier infection histories during a SARS-CoV-2 outbreak in Shanghai in spring 2022. Compared to an earlier patient cohort infected by SARS-CoV-2 prototype strains in 2020, BA.2.2 infection led to distinct fluctuations of pathophysiological markers in the peripheral blood. In particular, severe/critical cases of COVID-19 post BA.2.2 infection were associated with less pro-inflammatory macrophage activation and stronger interferon alpha response in the bronchoalveolar microenvironment. Importantly, the abnormal biomarkers were significantly subdued in individuals who had been immunized by 2 or 3 doses of SARS-CoV-2 prototype-inactivated vaccines, supporting the estimation of an overall 96.02% of protection rate against severe/critical disease in the 4854 cases in our BA.2.2 patient cohort with traceable vaccination records. Furthermore, even though age was a critical risk factor of the severity of COVID-19 post BA.2.2 infection, vaccination-elicited protection against severe/critical COVID-19 reached 90.15% in patients aged ≥ 60 years old. Together, our study delineates the pathophysiological features of Omicron BA.2.2 sublineages and demonstrates significant protection conferred by prior prototype-based inactivated vaccines.

Key words： SARS-CoV-2 COVID-19 host response bronchoalveolar lavage fluid (BALF)

收稿日期: 2022-11-30 出版日期: 2023-07-28

Corresponding Author(s): Saijuan Chen,Feng Liu,Yun Tan,Xiaohong Fan

引用本文:

. [J]. Frontiers of Medicine, 2023, 17(3): 562-575.
Ziyu Fu, Dongguo Liang, Wei Zhang, Dongling Shi, Yuhua Ma, Dong Wei, Junxiang Xi, Sizhe Yang, Xiaoguang Xu, Di Tian, Zhaoqing Zhu, Mingquan Guo, Lu Jiang, Shuting Yu, Shuai Wang, Fangyin Jiang, Yun Ling, Shengyue Wang, Saijuan Chen, Feng Liu, Yun Tan, Xiaohong Fan. Host protection against Omicron BA.2.2 sublineages by prior vaccination in spring 2022 COVID-19 outbreak in Shanghai. Front. Med., 2023, 17(3): 562-575.

链接本文:

https://academic.hep.com.cn/fmd/CN/10.1007/s11684-022-0977-3
https://academic.hep.com.cn/fmd/CN/Y2023/V17/I3/562

Fig.1

Fig.2

Fig.3

Fig.4

Fig.5

1	R Viana, S Moyo, DG Amoako, H Tegally, C Scheepers, CL Althaus, UJ Anyaneji, PA Bester, MF Boni, M Chand, WT Choga, R Colquhoun, M Davids, K Deforche, D Doolabh, L du Plessis, S Engelbrecht, J Everatt, J Giandhari, M Giovanetti, D Hardie, V Hill, NY Hsiao, A Iranzadeh, A Ismail, C Joseph, R Joseph, L Koopile, SL Kosakovsky Pond, MUG Kraemer, L Kuate-Lere, O Laguda-Akingba, O Lesetedi-Mafoko, RJ Lessells, S Lockman, AG Lucaci, A Maharaj, B Mahlangu, T Maponga, K Mahlakwane, Z Makatini, G Marais, D Maruapula, K Masupu, M Matshaba, S Mayaphi, N Mbhele, MB Mbulawa, A Mendes, K Mlisana, A Mnguni, T Mohale, M Moir, K Moruisi, M Mosepele, G Motsatsi, MS Motswaledi, T Mphoyakgosi, N Msomi, PN Mwangi, Y Naidoo, N Ntuli, M Nyaga, L Olubayo, S Pillay, B Radibe, Y Ramphal, U Ramphal, JE San, L Scott, R Shapiro, L Singh, P Smith-Lawrence, W Stevens, A Strydom, K Subramoney, N Tebeila, D Tshiabuila, J Tsui, S van Wyk, S Weaver, CK Wibmer, E Wilkinson, N Wolter, AE Zarebski, B Zuze, D Goedhals, W Preiser, F Treurnicht, M Venter, C Williamson, OG Pybus, J Bhiman, A Glass, DP Martin, A Rambaut, S Gaseitsiwe, A von Gottberg, T de Oliveira. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 2022; 603(7902): 679–686 https://doi.org/10.1038/s41586-022-04411-y pmid: 35042229
2	V Servellita, AM Syed, MK Morris, N Brazer, P Saldhi, M Garcia-Knight, B Sreekumar, MM Khalid, A Ciling, PY Chen, GR Kumar, AS Gliwa, J Nguyen, A Sotomayor-Gonzalez, Y Zhang, E Frias, J Prostko, J Jr Hackett, R Andino, DA Wadford, C Hanson, J Doudna, M Ott, CY Chiu. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell 2022; 185(9): 1539–1548.e5 https://doi.org/10.1016/j.cell.2022.03.019 pmid: 35429436
3	C Kurhade, J Zou, H Xia, H Cai, Q Yang, M Cutler, D Cooper, A Muik, KU Jansen, X Xie, KA Swanson, PY Shi. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nat Commun 2022; 13(1): 3602 https://doi.org/10.1038/s41467-022-30681-1 pmid: 35739094
4	Y Cao, J Wang, F Jian, T Xiao, W Song, A Yisimayi, W Huang, Q Li, P Wang, R An, J Wang, Y Wang, X Niu, S Yang, H Liang, H Sun, T Li, Y Yu, Q Cui, S Liu, X Yang, S Du, Z Zhang, X Hao, F Shao, R Jin, X Wang, J Xiao, Y Wang, XS Xie. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2022; 602(7898): 657–663 https://doi.org/10.1038/s41586-021-04385-3 pmid: 35016194
5	X Zhang, W Zhang, S Chen. Shanghai’s life-saving efforts against the current omicron wave of the COVID-19 pandemic. Lancet 2022; 399(10340): 2011–2012 https://doi.org/10.1016/S0140-6736(22)00838-8 pmid: 35533708
6	Y Ling, G Lu, F Liu, Y Tan, X Xu, D Wei, J Xu, S Wang, S Yu, F Jiang, X Zhang, S Chen, S Wang, X Fan, S Chen. The Omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring 2022. Cell Discov 2022; 8(1): 97 https://doi.org/10.1038/s41421-022-00468-1 pmid: 36167678
7	PV Markov, A Katzourakis, NI Stilianakis. Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity. Nat Rev Microbiol 2022; 20(5): 251–252 https://doi.org/10.1038/s41579-022-00722-z pmid: 35288685
8	JL Schultze, AC Aschenbrenner. COVID-19 and the human innate immune system. Cell 2021; 184(7): 1671–1692 https://doi.org/10.1016/j.cell.2021.02.029 pmid: 33743212
9	A Sette, S Crotty. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 2021; 184(4): 861–880 https://doi.org/10.1016/j.cell.2021.01.007 pmid: 33497610
10	X Zhang, Y Tan, Y Ling, G Lu, F Liu, Z Yi, X Jia, M Wu, B Shi, S Xu, J Chen, W Wang, B Chen, L Jiang, S Yu, J Lu, J Wang, M Xu, Z Yuan, Q Zhang, X Zhang, G Zhao, S Wang, S Chen, H Lu. Viral and host factors related to the clinical outcome of COVID-19. Nature 2020; 583(7816): 437–440 https://doi.org/10.1038/s41586-020-2355-0 pmid: 32434211
11	F Zhou, T Yu, R Du, G Fan, Y Liu, Z Liu, J Xiang, Y Wang, B Song, X Gu, L Guan, Y Wei, H Li, X Wu, J Xu, S Tu, Y Zhang, H Chen, B Cao. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054–1062 https://doi.org/10.1016/S0140-6736(20)30566-3 pmid: 32171076
12	G Bálint, B Vörös-Horváth, A Széchenyi. Omicron: increased transmissibility and decreased pathogenicity. Signal Transduct Target Ther 2022; 7(1): 151 https://doi.org/10.1038/s41392-022-01009-8 pmid: 35525870
13	J Ai, X Wang, X He, X Zhao, Y Zhang, Y Jiang, M Li, Y Cui, Y Chen, R Qiao, L Li, L Yang, Y Li, Z Hu, W Zhang, P Wang. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages. Cell Host Microbe 2022; 30(8): 1077–1083.e4 https://doi.org/10.1016/j.chom.2022.05.001 pmid: 35594867
14	Y Cao, A Yisimayi, F Jian, W Song, T Xiao, L Wang, S Du, J Wang, Q Li, X Chen, Y Yu, P Wang, Z Zhang, P Liu, R An, X Hao, Y Wang, J Wang, R Feng, H Sun, L Zhao, W Zhang, D Zhao, J Zheng, L Yu, C Li, N Zhang, R Wang, X Niu, S Yang, X Song, Y Chai, Y Hu, Y Shi, L Zheng, Z Li, Q Gu, F Shao, W Huang, R Jin, Z Shen, Y Wang, X Wang, J Xiao, XS Xie. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022; 608(7923): 593–602 https://doi.org/10.1038/s41586-022-04980-y pmid: 35714668
15	W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, HME Duyvesteyn, HM Ginn, AJ Mentzer, A Tuekprakhon, R Nutalai, B Wang, A Dijokaite, S Khan, O Avinoam, M Bahar, D Skelly, S Adele, SA Johnson, A Amini, TG Ritter, C Mason, C Dold, D Pan, S Assadi, A Bellass, N Omo-Dare, D Koeckerling, A Flaxman, D Jenkin, PK Aley, M Voysey, Clemens SA Costa, FG Naveca, V Nascimento, F Nascimento, da Costa C Fernandes, PC Resende, A Pauvolid-Correa, MM Siqueira, V Baillie, N Serafin, G Kwatra, Silva K Da, SA Madhi, MC Nunes, T Malik, PJM Openshaw, JK Baillie, MG Semple, AR Townsend, KA Huang, TK Tan, MW Carroll, P Klenerman, E Barnes, SJ Dunachie, B Constantinides, H Webster, D Crook, AJ Pollard, T; OPTIC Consortium; ISARIC4C Consortium Lambe, NG Paterson, MA Williams, DR Hall, EE Fry, J Mongkolsapaya, J Ren, G Schreiber, DI Stuart, GR Screaton. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 2022; 185(3): 467–484.e15 https://doi.org/10.1016/j.cell.2021.12.046 pmid: 35081335
16	S Iketani, L Liu, Y Guo, L Liu, JF Chan, Y Huang, M Wang, Y Luo, J Yu, H Chu, KK Chik, TT Yuen, MT Yin, ME Sobieszczyk, Y Huang, KY Yuen, HH Wang, Z Sheng, DD Ho. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 2022; 604(7906): 553–556 https://doi.org/10.1038/s41586-022-04594-4 pmid: 35240676
17	DH Barouch. Covid-19 vaccines—immunity, variants, boosters. N Engl J Med 2022; 387(11): 1011–1020 https://doi.org/10.1056/NEJMra2206573 pmid: 36044620
18	Y Tan, W Zhang, Z Zhu, N Qiao, Y Ling, M Guo, T Yin, H Fang, X Xu, G Lu, P Zhang, S Yang, Z Fu, D Liang, Y Xie, R Zhang, L Jiang, S Yu, J Lu, F Jiang, J Chen, C Xiao, S Wang, S Chen, XW Bian, H Lu, F Liu, S Chen. Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. Cell Discov 2021; 7(1): 42 https://doi.org/10.1038/s41421-021-00274-1 pmid: 34103487
19	B Langmead, SL Salzberg. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9(4): 357–359 https://doi.org/10.1038/nmeth.1923 pmid: 22388286
20	A Dobin, CA Davis, F Schlesinger, J Drenkow, C Zaleski, S Jha, P Batut, M Chaisson, TR Gingeras. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 2013; 29(1): 15–21 https://doi.org/10.1093/bioinformatics/bts635 pmid: 23104886
21	S Anders, PT Pyl, W Huber. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 2015; 31(2): 166–169 https://doi.org/10.1093/bioinformatics/btu638 pmid: 25260700
22	MI Love, W Huber, S Anders. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15(12): 550 https://doi.org/10.1186/s13059-014-0550-8 pmid: 25516281
23	CB Steen, CL Liu, AA Alizadeh, AM Newman. Profiling cell type abundance and expression in bulk tissues with CIBERSORTx. Methods Mol Biol 2020; 2117: 135–157 https://doi.org/10.1007/978-1-0716-0301-7_7 pmid: 31960376
24	Y Ling, G Lu, F Liu, Y Tan, X Xu, D Wei, J Xu, S Wang, S Yu, F Jiang, X Zhang, S Chen, S Wang, X Fan, S Chen. The Omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring 2022. Cell Discov 2022; 8(1): 97 https://doi.org/10.1038/s41421-022-00468-1 pmid: 36167678
25	Y Tan, F Liu, X Xu, Y Ling, W Huang, Z Zhu, M Guo, Y Lin, Z Fu, D Liang, T Zhang, J Fan, M Xu, H Lu, S Chen. Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. Front Med 2020; 14(6): 746–751 https://doi.org/10.1007/s11684-020-0822-5 pmid: 33017040
26	J Zhong, S Liu, T Cui, J Li, F Zhu, N Zhong, W Huang, Z Zhao, Z Wang. Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants. Emerg Microbes Infect 2022; 11(1): 2689–2697 https://doi.org/10.1080/22221751.2022.2132881 pmid: 36197655
27	Y Zhang, G Zeng, H Pan, C Li, Y Hu, K Chu, W Han, Z Chen, R Tang, W Yin, X Chen, Y Hu, X Liu, C Jiang, J Li, M Yang, Y Song, X Wang, Q Gao, F Zhu. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21(2): 181–192 https://doi.org/10.1016/S1473-3099(20)30843-4 pmid: 33217362
28	DR Feikin, MM Higdon, LJ Abu-Raddad, N Andrews, R Araos, Y Goldberg, MJ Groome, A Huppert, KL O’Brien, PG Smith, A Wilder-Smith, S Zeger, Knoll M Deloria, MK Patel. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet 2022; 399(10328): 924–944 https://doi.org/10.1016/S0140-6736(22)00152-0 pmid: 35202601
29	T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn, N Peiffer-Smadja. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect 2022; 28(2): 202–221 https://doi.org/10.1016/j.cmi.2021.10.005 pmid: 34715347
30	WHO. COVID-19 Weekly Epidemiological Update (Edition 115). 2022
31	Prost N de, E Audureau, N Heming, E Gault, T Pham, A Chaghouri, Montmollin N de, G Voiriot, L Morand-Joubert, A Joseph, ML Chaix, S Préau, R Favory, A Guigon, CE Luyt, S Burrel, J Mayaux, S Marot, D Roux, D Descamps, S Meireles, F Pène, F Rozenberg, D Contou, A Henry, S Gaudry, S Brichler, JF Timsit, A Kimmoun, C Hartard, LM Jandeaux, S Fafi-Kremer, P Gabarre, M Emery, C Garcia-Sanchez, S Jochmans, A Pitsch, D Annane, E Azoulay, Dessap A Mekontso, C Rodriguez, JM Pawlotsky, S Fourati. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. Nat Commun 2022; 13(1): 6025 https://doi.org/10.1038/s41467-022-33801-z pmid: 36224216
32	N Chen, M Zhou, X Dong, J Qu, F Gong, Y Han, Y Qiu, J Wang, Y Liu, Y Wei, J Xia, T Yu, X Zhang, L Zhang. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513 https://doi.org/10.1016/S0140-6736(20)30211-7 pmid: 32007143
33	M Antonelli, JC Pujol, TD Spector, S Ourselin, CJ Steves. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022; 399(10343): 2263–2264 https://doi.org/10.1016/S0140-6736(22)00941-2 pmid: 35717982
34	SM Vora, J Lieberman, H Wu. Inflammasome activation at the crux of severe COVID-19. Nat Rev Immunol 2021; 21(11): 694–703 https://doi.org/10.1038/s41577-021-00588-x pmid: 34373622
35	B Kerget, F Kerget, A Aksakal, S Aşkın, L Sağlam, M Akgün. Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome. J Med Virol 2021; 93(4): 2090–2098 https://doi.org/10.1002/jmv.26589 pmid: 33038012
36	RN Hanna, I Shaked, HG Hubbeling, JA Punt, R Wu, E Herrley, C Zaugg, H Pei, F Geissmann, K Ley, CC Hedrick. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ Res 2012; 110(3): 416–427 https://doi.org/10.1161/CIRCRESAHA.111.253377 pmid: 22194622
37	L Dai, GF Gao. Viral targets for vaccines against COVID-19. Nat Rev Immunol 2021; 21(2): 73–82 https://doi.org/10.1038/s41577-020-00480-0 pmid: 33340022
38	Ministry-of-Health-Singapore. COVID-19 Statistics. 2022
39	China-Government-Network. The latest news on epidemic prevention and control of SARS-CoV-2 on April 28. 2022
40	Live-Shanghai. Build a strong immune “firewall”! Increase the vaccination rate of the elderly and other groups, and complete the booster immunization as soon as possible. 2022

[1]	FMD-22054-OF-TY_suppl_1	Download
[2]	FMD-22054-OF-TY_suppl_2	Download

Viewed

Full text

Abstract

Cited

Shared

Discussed